Duchenne Muscular Dystrophy Treatment Market 2034: FDA Approvals, Clinical Trials, Medication, Epidemiology, Drugs and Companies by DelveInsight | Pfizer, FibroGen, Roche, Capricor Therapeutics, Italfarmaco, Antisense Therapeutics, Sarepta, ReveraGen Biop

(Albany, USA) DelveInsight's "Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Duchenne Muscular Dystrophy, historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Duchenne Muscular Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Duchenne Muscular Dystrophy Market Forecast
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Duchenne Muscular Dystrophy Market Report:
• The Duchenne Muscular Dystrophy market size was valued approximately USD 1,700 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In 2034, the estimated number of prevalent cases of Duchenne Muscular Dystrophy (DMD) in the seven major markets (7MM) was approximately 34,000.
• In 2022, within the United States, the greatest percentage of cases specific to particular age groups were noted in the range of 5 to 9 years old, followed by the age brackets of 10 to 14 years and 15 to 20 years.
• In the United States, among individuals diagnosed with Duchenne Muscular Dystrophy (DMD), the highest recorded prevalence of associated comorbidities was observed in the case of Scoliosis, reaching approximately 4,000 cases in 2022.
• In the EU4 countries (Germany, France, Italy, and Spain) along with the United Kingdom, the highest prevalence of Duchenne Muscular Dystrophy (DMD) was observed in the UK, totaling approximately 3,000 cases in 2022. This was followed by Germany and France, whereas Spain had the lowest number of cases recorded in the same year.
• In the present US market, there are several approved products-EMFLAZA (deflazacort), VYONDYS 53 (golodirsen), EXONDYS 51 (eteplirsen), AMONDYS 45 (casimersen), and VILTEPSO (viltolarsen)-available for individuals with Duchenne Muscular Dystrophy (DMD). Within the EU4 countries and the UK, steroid therapies dominate the current market, accompanied by an approved medication designed for DMD patients with the nonsense mutation, TRANSLARNA (ataluren). However, in Japan, the sole approved treatment available is VILTEPSO (viltolarsen).
• Key Duchenne Muscular Dystrophy Companies: Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals/ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics, Fibrogen, Roche/Sarepta Therapeutics, Edgewise Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, and others
• Key Duchenne Muscular Dystrophy Therapies: Givinostat (ITF2357), ATL1102, SRP-9001, Vamorolone, PF06939926, Pamrevlumab, CAP-1002, Pamrevlumab, Delandistrogene moxeparvovec, EDG 5506, WVE N531, PGN EDO51, UX810, and others
• The Duchenne Muscular Dystrophy epidemiology based on gender analyzed that Duchenne Muscular Dystrophy rarely affects females
• The Duchenne Muscular Dystrophy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Duchenne Muscular Dystrophy pipeline products will significantly revolutionize the Duchenne Muscular Dystrophy market dynamics.

Duchenne Muscular Dystrophy Overview
Duchenne Muscular Dystrophy (DMD) is a severe, progressive genetic disorder characterized by muscle degeneration and weakness. It is caused by mutations in the Duchenne Muscular Dystrophy gene, which encodes dystrophin, a protein essential for maintaining the structural integrity of muscle fibers. The lack of functional dystrophin leads to muscle damage and the replacement of muscle tissue with fat and fibrous tissue over time.
Duchenne Muscular Dystrophy primarily affects boys, with symptoms typically appearing between ages 2 and 5. Early signs include delayed motor milestones, difficulty running or jumping, frequent falls, and a waddling gait. As the disease progresses, muscle weakness extends to the upper body, and by the early teens, most patients require wheelchair assistance. Respiratory and cardiac complications often develop in the later stages, significantly impacting life expectancy, which has improved with advancements in care but still often does not extend beyond the third decade of life.
Management of Duchenne Muscular Dystrophy involves a multidisciplinary approach to slow disease progression and improve quality of life. This includes physical therapy, corticosteroids to maintain muscle strength, cardiac and respiratory care, and orthopedic interventions. Recent advancements in gene therapy, exon skipping, and other molecular approaches hold promise for more effective treatments, aiming to address the underlying genetic defect and improve outcomes for those with Duchenne Muscular Dystrophy. Continued research and clinical trials are crucial for developing new therapies and enhancing patient care.

Get a Free sample for the Duchenne Muscular Dystrophy Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Duchenne Muscular Dystrophy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Duchenne Muscular Dystrophy Epidemiology Segmentation:
The Duchenne Muscular Dystrophy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Duchenne Muscular Dystrophy
• Prevalent Cases of Duchenne Muscular Dystrophy by severity
• Gender-specific Prevalence of Duchenne Muscular Dystrophy
• Diagnosed Cases of Episodic and Chronic Duchenne Muscular Dystrophy

Download the report to understand which factors are driving Duchenne Muscular Dystrophy epidemiology trends @ Duchenne Muscular Dystrophy Epidemiology Forecast
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Duchenne Muscular Dystrophy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Duchenne Muscular Dystrophy market or expected to get launched during the study period. The analysis covers Duchenne Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Duchenne Muscular Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Duchenne Muscular Dystrophy Therapies and Key Companies
• Givinostat (ITF2357): Italfarmaco
• ATL1102: Antisense Therapeutics
• SRP-9001: Sarepta Therapeutics
• Vamorolone: Santhera Pharmaceuticals/ReveraGen Biopharma
• PF06939926: Pfizer
• Pamrevlumab: FibroGen
• CAP-1002: Capricor Therapeutics
• Pamrevlumab: Fibrogen
• Delandistrogene moxeparvovec: Roche/Sarepta Therapeutics
• EDG 5506: Edgewise Therapeutics
• WVE N531: Wave Life Sciences Ltd
• PGN EDO51: PepGen
• UX810: Ultragenyx Pharmaceutical

Discover more about therapies set to grab major Duchenne Muscular Dystrophy market share @ Duchenne Muscular Dystrophy Treatment Landscape
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Duchenne Muscular Dystrophy Market Strengths
• The pipeline of DMD is robust with the advent of several potential products in late-stage of clinical development.
• Several new therapies have been approved for the treatment of DMD recently, even Japan has witnessed the launch of VILTEPSO now.

Duchenne Muscular Dystrophy Market Opportunities
• Wider commercial opportunity for therapies such as Capricor's CAP-1002 and Antisense's ATL1102, which are specifically focusing on improving upper limb functions in DMD patients and are targeting a much larger patient segment when compared to the Exon-Skipping therapies.

Scope of the Duchenne Muscular Dystrophy Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Duchenne Muscular Dystrophy Companies: Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals/ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics, Fibrogen, Roche/Sarepta Therapeutics, Edgewise Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, and others
• Key Duchenne Muscular Dystrophy Therapies: Givinostat (ITF2357), ATL1102, SRP-9001, Vamorolone, PF06939926, Pamrevlumab, CAP-1002, Pamrevlumab, Delandistrogene moxeparvovec, EDG 5506, WVE N531, PGN EDO51, UX810, and others
• Duchenne Muscular Dystrophy Therapeutic Assessment: Duchenne Muscular Dystrophy current marketed and Duchenne Muscular Dystrophy emerging therapies
• Duchenne Muscular Dystrophy Market Dynamics: Duchenne Muscular Dystrophy market drivers and Duchenne Muscular Dystrophy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Duchenne Muscular Dystrophy Unmet Needs, KOL's views, Analyst's views, Duchenne Muscular Dystrophy Market Access and Reimbursement

To know more about Duchenne Muscular Dystrophy companies working in the treatment market, visit @ Duchenne Muscular Dystrophy Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Duchenne Muscular Dystrophy Market Report Introduction
2. Executive Summary for Duchenne Muscular Dystrophy
3. SWOT analysis of Duchenne Muscular Dystrophy
4. Duchenne Muscular Dystrophy Patient Share (%) Overview at a Glance
5. Duchenne Muscular Dystrophy Market Overview at a Glance
6. Duchenne Muscular Dystrophy Disease Background and Overview
7. Duchenne Muscular Dystrophy Epidemiology and Patient Population
8. Country-Specific Patient Population of Duchenne Muscular Dystrophy
9. Duchenne Muscular Dystrophy Current Treatment and Medical Practices
10. Duchenne Muscular Dystrophy Unmet Needs
11. Duchenne Muscular Dystrophy Emerging Therapies
12. Duchenne Muscular Dystrophy Market Outlook
13. Country-Wise Duchenne Muscular Dystrophy Market Analysis (2020-2034)
14. Duchenne Muscular Dystrophy Market Access and Reimbursement of Therapies
15. Duchenne Muscular Dystrophy Market Drivers
16. Duchenne Muscular Dystrophy Market Barriers
17. Duchenne Muscular Dystrophy Appendix
18. Duchenne Muscular Dystrophy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Report :
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Alstrom Syndrome Market: https://www.delveinsight.com/report-store/bardet-biedl-syndrome-market
• Arteriovenous Fistula Market: https://www.delveinsight.com/report-store/arteriovenous-fistula-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Post-transplant Lymphoproliferative Disease Market: https://www.delveinsight.com/report-store/post-transplant-lymphoproliferative-disorder-market
• Adult Onset Still Disease Market: https://www.delveinsight.com/report-store/adult-onset-still-disease-market
• Cardiac Resynchronization Therapy Device Market: https://www.delveinsight.com/report-store/cardiac-resynchronization-therapy-market
• Chronic Inflammatory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Carcinoid Tumor Market: https://www.delveinsight.com/report-store/neuroendocrine-tumors-market
• Nsclc Market: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
• Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Bronchiolitis Obliterans Syndrome Bos Market: https://www.delveinsight.com/report-store/bronchiolitis-obliterans-syndrome-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/report-store/necrotizing-enterocolitis-nec-epidemiology-forecast
• Acute Coronary Syndrome Market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
• Epilepsy Market: https://www.delveinsight.com/report-store/epilepsy-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Progressive Familial Intrahepatic Cholestasis Market: https://www.delveinsight.com/report-store/progressive-familial-intrahepatic-cholestasis-pfic-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Cervical Cancer Market Size: https://www.delveinsight.com/report-store/cervical-cancer-market
• Chronic Lymphocytic Leukemia Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Neurotrophic Keratitis Market: https://www.delveinsight.com/report-store/neurotrophic-keratitis-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Optic Neuritis Market: https://www.delveinsight.com/report-store/optic-neuritis-market
• Spasticity Market: https://www.delveinsight.com/report-store/spasticity-market
• Surgical Stapling Devices Market: https://www.delveinsight.com/report-store/surgical-stapling-devices-market
• Thrombotic Microangiopathy Market: https://www.delveinsight.com/report-store/thrombotic-microangiopathy-tma-market
• Vestibular Schwannoma Market: https://www.delveinsight.com/report-store/vestibular-schwannoma-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.